BR112016008062A2 - - Google Patents
Info
- Publication number
- BR112016008062A2 BR112016008062A2 BR112016008062A BR112016008062A BR112016008062A2 BR 112016008062 A2 BR112016008062 A2 BR 112016008062A2 BR 112016008062 A BR112016008062 A BR 112016008062A BR 112016008062 A BR112016008062 A BR 112016008062A BR 112016008062 A2 BR112016008062 A2 BR 112016008062A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13188904 | 2013-10-16 | ||
| EP13188904.0 | 2013-10-16 | ||
| PCT/EP2014/072085 WO2015055698A1 (en) | 2013-10-16 | 2014-10-15 | Piperazine derivatives and the use thereof as medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016008062A2 true BR112016008062A2 (pt) | 2017-08-01 |
| BR112016008062B1 BR112016008062B1 (pt) | 2022-11-16 |
Family
ID=49354583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016008062-9A BR112016008062B1 (pt) | 2013-10-16 | 2014-10-15 | Derivados de piperazina, uso dos mesmos, composição farmacêutica e medicamento que os compreende e combinação |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9233953B2 (pt) |
| EP (1) | EP3057963B1 (pt) |
| JP (1) | JP6483105B2 (pt) |
| KR (1) | KR102281284B1 (pt) |
| CN (1) | CN105636961B (pt) |
| AR (1) | AR098037A1 (pt) |
| AU (1) | AU2014336258B2 (pt) |
| BR (1) | BR112016008062B1 (pt) |
| CA (1) | CA2926754C (pt) |
| CL (1) | CL2016000884A1 (pt) |
| DK (1) | DK3057963T3 (pt) |
| EA (1) | EA029313B1 (pt) |
| ES (1) | ES2745555T3 (pt) |
| HU (1) | HUE047044T2 (pt) |
| IL (1) | IL244693B (pt) |
| MX (1) | MX370006B (pt) |
| PH (1) | PH12016500577B1 (pt) |
| PL (1) | PL3057963T3 (pt) |
| TW (1) | TW201609716A (pt) |
| UY (1) | UY35785A (pt) |
| WO (1) | WO2015055698A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106854189A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种哌嗪化合物的合成方法 |
| CN107778257A (zh) * | 2016-08-29 | 2018-03-09 | 湖南华腾制药有限公司 | 一种哌嗪衍生物的合成方法 |
| CN106977463A (zh) * | 2017-05-31 | 2017-07-25 | 湖南华腾制药有限公司 | 一种联苯取代哌嗪衍生物的合成方法 |
| CN107417679A (zh) * | 2017-08-04 | 2017-12-01 | 河南农业大学 | 1,3‑唑类取代吡嗪类化合物的制备方法 |
| EP4087570A4 (en) | 2020-01-09 | 2024-04-03 | Disc Medicine, Inc. | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| GB0505085D0 (en) | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
| WO2006113704A2 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| CN102574857B (zh) | 2009-07-08 | 2015-06-10 | 利奥制药有限公司 | 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物 |
-
2014
- 2014-10-14 US US14/513,918 patent/US9233953B2/en active Active
- 2014-10-15 PL PL14784235T patent/PL3057963T3/pl unknown
- 2014-10-15 CN CN201480056368.8A patent/CN105636961B/zh active Active
- 2014-10-15 AR ARP140103834A patent/AR098037A1/es unknown
- 2014-10-15 BR BR112016008062-9A patent/BR112016008062B1/pt active IP Right Grant
- 2014-10-15 DK DK14784235.5T patent/DK3057963T3/da active
- 2014-10-15 HU HUE14784235A patent/HUE047044T2/hu unknown
- 2014-10-15 TW TW103135739A patent/TW201609716A/zh unknown
- 2014-10-15 JP JP2016523968A patent/JP6483105B2/ja active Active
- 2014-10-15 WO PCT/EP2014/072085 patent/WO2015055698A1/en active Application Filing
- 2014-10-15 ES ES14784235T patent/ES2745555T3/es active Active
- 2014-10-15 KR KR1020167012860A patent/KR102281284B1/ko active IP Right Grant
- 2014-10-15 CA CA2926754A patent/CA2926754C/en active Active
- 2014-10-15 EA EA201600323A patent/EA029313B1/ru not_active IP Right Cessation
- 2014-10-15 AU AU2014336258A patent/AU2014336258B2/en active Active
- 2014-10-15 EP EP14784235.5A patent/EP3057963B1/en active Active
- 2014-10-15 MX MX2016004847A patent/MX370006B/es active IP Right Grant
- 2014-10-16 UY UY0001035785A patent/UY35785A/es unknown
-
2016
- 2016-03-21 IL IL244693A patent/IL244693B/en active IP Right Grant
- 2016-03-30 PH PH12016500577A patent/PH12016500577B1/en unknown
- 2016-04-14 CL CL2016000884A patent/CL2016000884A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016500577A1 (en) | 2016-06-20 |
| HUE047044T2 (hu) | 2020-04-28 |
| MX370006B (es) | 2019-11-28 |
| JP2016533368A (ja) | 2016-10-27 |
| NZ718251A (en) | 2021-02-26 |
| IL244693A0 (en) | 2016-04-21 |
| TW201609716A (zh) | 2016-03-16 |
| CL2016000884A1 (es) | 2016-12-30 |
| ES2745555T3 (es) | 2020-03-02 |
| US9233953B2 (en) | 2016-01-12 |
| US20150105397A1 (en) | 2015-04-16 |
| AU2014336258B2 (en) | 2018-07-12 |
| WO2015055698A1 (en) | 2015-04-23 |
| EA201600323A1 (ru) | 2016-10-31 |
| EA029313B1 (ru) | 2018-03-30 |
| KR20160062187A (ko) | 2016-06-01 |
| AU2014336258A1 (en) | 2016-04-14 |
| DK3057963T3 (da) | 2019-09-16 |
| PL3057963T3 (pl) | 2019-12-31 |
| JP6483105B2 (ja) | 2019-03-13 |
| BR112016008062B1 (pt) | 2022-11-16 |
| KR102281284B1 (ko) | 2021-07-23 |
| IL244693B (en) | 2019-08-29 |
| EP3057963B1 (en) | 2019-06-19 |
| CA2926754C (en) | 2021-09-14 |
| PH12016500577B1 (en) | 2016-06-20 |
| CA2926754A1 (en) | 2015-04-23 |
| EP3057963A1 (en) | 2016-08-24 |
| MX2016004847A (es) | 2016-07-19 |
| UY35785A (es) | 2015-04-30 |
| AR098037A1 (es) | 2016-04-27 |
| CN105636961A (zh) | 2016-06-01 |
| CN105636961B (zh) | 2019-11-05 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2014, OBSERVADAS AS CONDICOES LEGAIS |